AVEO Pharmaceuticals (AVEO) said it secured a clinical trial partnership and supply agreement in North America with Eli Lilly and Co. (LLY) to assess...
...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
AVEO Pharmaceuticals (AVEO) reported a Q4 net loss Monday of $0.21 per share, compared with a loss of $0.44 a year earlier. Analysts polled by Capital IQ...
| Address | 30 Winter Street Boston, Massachusetts 02108 |
| Phone | +1.617.400.0101 |
| Number of Employees | 17 |
| Recent SEC Filing | 06/08/2022 4 |
| President, Chief Executive Officer & Director | Michael P. Bailey |
| Chief Operating Officer | Jebediah Ledell |
| Chief Financial Officer | Erick J. Lucera |
| Vice President-Information Technology | Matthew Coulter |
| Price Open | $6.50 |
| Previous Close | $6.58 |
| 52 Week Range | $3.06 - 7.55 |
| Market Capitalization | $231.3 M |
| Shares Outstanding | 34.5 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.26 |
| Beta vs. S&P 500 | N/A |
| Revenue | $5.4 M |
| Net Profit Margin | -67.57% |
| Return on Equity | -85.29% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
